|
|
|
| Clinical Characteristics of Corona Virus Disease 2019 and Effectiveness Analysis of Convalescent Plasma |
| SHEN Daoqian, YANG Jingli, et al |
| The People's Hospital of Zhangjiajie, Hunan Zhangjiajie 427000, China |
|
|
|
|
Abstract Objective: To investigate the clinical characteristics of Corona Virus Disease 2019 (COVID-19) efficacy of convalescent plasma therapy. Methods: A total of 6 cases COVID-19 patients admitted to Wuhan Jinyintan Hospital and received convalescent plasma therapy from January 23, 2020 to April 26, 2020 were reviewed retrospectively, and the clinical characteristics as well as efficacy of convalescent plasma therapy were summarized and analyzed respectively. Results: According to the guideline for Diagnosis and Treatment of Novel Coronavirus Infected Pneumonia, 6 cases were divided into severe group (n=4) and critical group (n=2). The clinical symptoms of 6 cases included fever (6 cases), cough (6 cases), fatigue (3 cases), diarrhea (1 case). Ratio of lymphocyte decreased in 3 patients. High sensitivity troponin and glutamic-pyruvic transaminase raised in one patient, respectively. The manifestations of early lung CT images in severe group were ground-glass-like high density shadows scattered outside the lungs. CT images in critical group showed that diffuse ground-glass-like high density shadows, or cotton ball-like and reticular nodules consolidation change were formed in both lungs. On the basis of antiviral therapy, 6 patients were administrated with convalescent plasma. All patients were successful in plasma transfusion except one, who had a skin allergy, and was relieved after symptomatic treatment. After active treatment, symptoms and various indicators of these patients were improved, and finally, all patients were cured and discharged. Conclusion: Fever and cough are the first symptoms of COVID-19, accompanied by different degrees of systemic symptoms, Plasma therapy in convalescent period has certain application value in treating COVID-19, but the potential side effects of blood transfusion should be paid attention to.
|
|
|
|
|
|
[1] Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)[J]. Mil Med Res. 2020, 7(1): 4.
[2] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China[J]. JAMA. 2020,323(11):1061~1069.
[3] 国家卫生健康委办公厅.国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18).http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml[J].
[4] Hui DS, IAE, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health- The latest 2019 novel coronavirus outbreak in Wuhan, China[J]. Int Infect Dis. 2020, 91(2020): 264~266.
[5] Koo HJ, Lim S, Choe J, et al. Radiographic and CT features of viral pneumonia[J]. Radiographics. 2018, 38(3): 719~739.
[6] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet. 2020, 395(10223): 497~506.
[7] 陈颖,姜玉华,李先鹏,等.新型冠状病毒肺炎11例临床特征及治疗方法[J].现代实用医学.2020,32(2):150~153.
[8] Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in middle east respiratory coronavirus infection: a single centre experience[J]. Antivir Ther. 2018, 23(7): 617~622.
[9] Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J]. Proc Natl Acad Sci U S A. 2020, 117(17): 9490~9496. |
| [1] |
. [J]. HeBei Med, 2020, 26(6): 881-886. |
|
|
|
|
2021, Vol. 27 
